{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:56:25Z","timestamp":1777614985254,"version":"3.51.4"},"reference-count":11,"publisher":"Informa Healthcare","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2012,7,1]]},"DOI":"10.1185\/03007995.2012.689956","type":"journal-article","created":{"date-parts":[[2012,5,2]],"date-time":"2012-05-02T05:58:50Z","timestamp":1335938330000},"page":"1167-1171","source":"Crossref","is-referenced-by-count":64,"title":["Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study"],"prefix":"10.1185","volume":"28","clinical-trial-number":[{"clinical-trial-number":"nct00642278","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"L.E.","family":"Nicolle","sequence":"first","affiliation":[{"name":"University of Manitoba\rWinnipegCanada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Capuano","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, NJUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ways","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, NJUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Usiskin","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Pharmaceutical Research & Development LLC, Raritan, NJUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2012,5,15]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3180"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01406.x"},{"key":"CIT0003","unstructured":"Rosenstock J, Arbit D, Usiskin K, et al. Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with Type 2 diabetes on metformin [abstract #77-OR]. American Diabetes Association 70th Scientific Sessions, 25\u201329 June 2010, Orlando, FL, USA"},{"key":"CIT0004","unstructured":"Rosenstock J, Polidori D, Zhao Y, et al. Canagliflozin, an inhibitor of sodium glucose co-transporter 2, improves glycemic control, lowers body weight, and improves beta-cell function in subjects with diabetes on background metformin [abstract]. 46th Annual Meeting of the European Association for the Study of Diabetes, 20\u201324 September 2010, Stockholm, Sweden"},{"key":"CIT0005","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Aggarwal N, Polidori D. et al. for the Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012 (in press)","DOI":"10.2337\/dc11-1926"},{"key":"CIT0006","doi-asserted-by":"crossref","unstructured":"Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012 (in press)","DOI":"10.1185\/03007995.2012.697053"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-48-6-535"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.2.316"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2043"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.6.744"},{"key":"CIT0011","doi-asserted-by":"crossref","unstructured":"Geerlings SE, Stolk RP, Camps MJ, et al. Diabetes Women Asymptomatic Bacteriuria Utrecht Study Group. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000;23:1737\u201341","DOI":"10.2337\/diacare.23.12.1737"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2012.689956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T04:28:45Z","timestamp":1597552125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2012.689956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,15]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7,1]]}},"alternative-id":["10.1185\/03007995.2012.689956"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2012.689956","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,15]]}}}